New Publication Guidance on gene replacement therapy in Spinal Muscular Atrophy: a Canadian perspective

The NMD4C is proud to announce that a Guidance on gene replacement therapy in Spinal Muscular Atrophy: a Canadian perspective has been accepted for publication by the Canadian Journal of Neurological Sciences. Notably this consensus statement is authored by NMD4C members Drs. Maryam Oskoui, Hernan Gonorazky, Hugh McMillan, James Dowling, Reshma Amin, Cynthia Gagnon, and Kathryn Selby.

This publication is the first significant research output of the NMD4C, and is a product of the network’s development, dissemination, and implementation of clinical guidelines working group. The working group invited pediatric neuromuscular clinical experts from across the country to provide feedback and direction in adapting existing consensus statements on gene replacement therapy in SMA to the Canadian context.

“It is an exciting time for the neuromuscular field with the advancement of gene therapies. It is our duty as neuromuscular specialists to advocate for safe, equitable, and transparent access to these treatments for all Canadians. We hope that through this consensus we can help inform the application, indication and use of gene replacement therapy in Spinal muscular atrophy.”

– Dr. Hernan Gonorazky.

You can find the publication here.

With three SMA therapies now commercially available in Canada, the working group set out to provide guidance by adapting a set of European consensus statements to a Canadian context and highlighting areas of future need for gene replacement therapy in SMA in Canada. The original publication  from an ad-hoc group of 13 European SMA experts who published a set of consensus statements on the use of gene replacement therapy in SMA using a Delphi consensus process.

The NMD4C will continue to work towards its knowledge translation (KT) goals to improve care standards, train the next generation of neuromuscular researchers and clinicians, and strengthen research infrastructure for better research and more treatments.

GuidanceSMApaper

Read next...

MDC and NMD4C now recruiting: clinical trials and community of practice manager

MDC and NMD4C Hiring Full-Time Clinical Trials and Community Practice Manager

Join our team of dedicated colleagues and volunteers in breaking down barriers for the neuromuscular community and help bring clinical trials to Canada!

2024 NMD4C early-career awards now accepting applications

Annual NMD4C Early-Career Awards Program Accepting Applications

We are excited to launch the second year of the NMD4C Early-Career Awards for 2024!

NMD4C pre-clinical science team seeking trainee input. Let us know if you'd like to be involved in an advisory committee.

NMD4C Pre-clinical Science Pillar Seeking Trainee Input

The NMD4C cell and animal-based research team is actively seeking the input of neuromuscular trainees to help inform our activities. If you are willing to participate in a committee that will meet periodically to share input on NMD4C cell and animal-based research activities, we want to hear from you! 

Dr Natasha Chang and Dr Rashmi Kothary receive MDC Dr David Green Awards in 2023.

NMD4C Investigators Dr Rashmi Kothary and Dr Natasha Chang Receive MDC Awards

We are excited to share that NMD4C investigators Dr Rashmi Kothary, and Dr Natasha Chang received the Dr George Karpati Award for Researcher of the Year and Rising Clinician/Researcher Award respectively from Muscular Dystrophy Canada

News update reading: Vamorolone receives approval by the FDA in the US and positive opinion from CHMP in the EU for use in the treatment of Duchenne muscular dystrophy.

Vamorolone receives approval by the FDA in the US and positive opinion from CHMP in the EU for use in the treatment of Duchenne muscular dystrophy.

The FDA approved vamorolone on October 26, 2023 for the treatment of DMD in the US, while the CHMP has issued a positive opinion for vamorolone for the treatment of DMD in the EU.

NMD4C members gather for a group photo at the annual meeting.

Annual NMD4C Meeting Recap

Thank you to everyone who attended the Annual NMD4C Meeting on September 7th in Ottawa! We were thrilled to welcome 84 network investigators, general members, patient partners and trainees to outline the network activities for the next five years and kick off our new grant period.    The meeting program consisted of presentations from task…